Drawing for COMBIMASC

USPTO serial 75913519

COMBIMASC

Reviewed by CopyMark Law Group

Filing date
Status date
Registration date
—
Examiner
CHARLON, BARNEY
Law office
FILE REPOSITORY (FRANCONIA)

What this means

These status codes mean the trademark application is abandoned and no longer pending. Common reasons include missing an Office Action response (600), filing without a valid basis (602), express abandonment by the applicant (604), or failure to respond to an examiner's inquiry (618). Revival may be possible in limited circumstances. If abandonment was unintentional, consult counsel about a petition to revive. Otherwise file a new application if protection is still needed.

Status 602: These status codes mean the trademark application is abandoned and no longer pending. Common reasons include missing an Office Action response (600), filing without a valid basis (602), express abandonment by the applicant (604), or failure to respond to an examiner's inquiry (618). Revival may be possible in limited circumstances.

Need help with COMBIMASC?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Donna J. Bunton

DONNA J BUNTON NIXON & VANDERHYE PC1100 N GLEBE RD 8TH FLARLINGTON, VA 22201UNITED STATES

Goods and services

ClassDescriptionStatusFirst use
001POLYMER DERIVATIVES AND POLYETHYLENE GLYCOLDERIVATIVES FOR USE IN THE MANUFACTURE OF THERAPEUTIC AND DIAGNOSTIC AGENTS AND IMAGING AGENTS FOR DIAGNOSTIC PURPOSES; POLYMER DERIVATIVES AND POLYETHYLENE GLYCOLDERIVATIVES FOR USE IN THE MANUFACTURE OF COSMETIC AND PHARMACEUTICAL PREPARATIONS AND SUBSTANCES; POLYMERBEADS FOR USE IN MANUFACTURING; POLYALKYLENE GLYCOLSFOR USE IN THE MANUFACTURE OF THERAPEUTIC AND DIAGNOSTIC AGENTS AND AS IMAGING AGENTS FOR DIAGNOSTIC PURPOSES; LIPOSOMES, PROTEINS AND PEPTIDES FOR USE IN THE MANUFACTURE OF PHARMACEUTICALS; DIAGNOSTIC AGENTS AND REAGENTS FOR MEDICAL RESEARCH USE; POLYMER MODIFIED COMPOUNDS FOR USE IN THE MANUFACTURE OF THERAPEUTIC AND DIAGNOSTIC AGENTS; IMAGING AGENTS FOR DIAGNOSTIC PURPOSESACTIVE—
003COSMETIC AND TOILETRY PRODUCTS CONTAINING POLYMER1~-DERIVATIVES; NAMELY, EAU DE COLOGNE, PERFUMES, SHAVING SOAP, TALCUM POWDER, DENTIFRICES, TOOTHPASTE, ESSENTIAL OILS FOR PERSONAL USE, BATH OILS AND BATH SALTS,DEODORANTS FOR PERSONAL USE, SOAPS, SKIN CREAMS AND SKIN LOTIONS, MOISTURIZING CREAMS, BODY LOTIONS, AFTERSHAVE, LIPSTICK, MASCARA, EYELINER, SKIN CLEANSERS,MAKE-UP POWDERS AND CREAMS; NAIL POLISH; HAIRCAREPRODUCTS, NAMELY, HAIR SHAMPOO, CONDITIONER AND GEL;HAIR COLORANTS AND HAIR SPRAYS; MOUSSES AND BALMS FOR HAIR STYLING AND HAIR CAREACTIVE—
005PHARMACEUTICAL AND VETERINARY PREPARATIONS AND SUBSTANCES; NAMELY, PROTEINS, PEPTIDES, AMINO ACIDS AND THEIR DERIVATIVES, NAMELY, ANTIBODIES AND FRAGMENTS THEREOF; CYTOKINES AND DERIVATIVES OR FRAGMENTS THEREOF, NAMELY, THE INTERLEUKINS (IL), ESPECIALLY THE IL-IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-b AND IL-li SUBTYPES THEREOF; COLONY STIMULATING FACTORS, NAMELY,GRANULOCYTE-MACROPHAGE COLONY STIMULATING FACTOR,GRANULOCYTE-COLONY STIMULATING FACTOR (ALPHA AND BETA FORMS) AND MACROPHAGE-COLONY STIMULATING FACTOR (ALSO KNOWN AS CSF-1); HAEMOPOIETINS, NAMELY, ERYTHROPOIETIN,HAEMOPOIETIN-ALPHA AND KIT-LIGAND (ALSO KNOWN AS STEMCELL FACTOR OR STEEL FACTOR); INTERFERONS (IFNS), NAMELY,IFNALPHA, IFNBETA, IFNGAMMA; GROWTH FACTORS ANDBIFUNCTIONAL GROWTH MODULATORS, NAMELY, EPIDERMAL GROWTH FACTOR, PLATELET-DERIVED GROWTH FACTOR,TRANSFORMING GROWTH FACTOR (ALPHA AND BETA FORMS),AMPHIREGULIN, SOMATOMEDIN-C, BONE GROWTH FACTOR,FIBROBLAST GROWTH FACTORS, INSULIN-LIKE GROWTH FACTORS,HERAPIN BINDING GROWTH FACTORS AND TUMOR GROWTH FACTORS; DIFFERENTIATION FACTORS AND THE LIKE, NAMELY,MACROPHAGE DIFFERENTIATING FACTOR, DIFFERENTIATION INDUCING FACTOR (DIF) AND LEUKEMIA INHIBITORY FACTOR;ACTIVATING FACTORS, NAMELY, PLATELET ACTIVATING FACTOR;COAGULATION FACTORS SUCH AS FIBRINOLYTIC/ANTICOAGULANT AGENTS INCLUDING HERAPIN AND PROTEASES AND THEIR PRO-FACTORS, NAMELY, CLOTTING FACTORS VII, VIII, IX, X, XI, XII, ANTITHROMBIN III, PROTEIN C, PROTEIN 5, STREPTOKINASE, UROKINASE, PROUROKINASE, TISSUE PLASMINOGEN ACTIVATOR, FIBRINOGEN AND HIRUDIN; PEPTIDE HORMONES, NAMELY, INSULIN AND CALCITONIN; ENZYMES, NAMELY, SUPEROXIDE DISMUTASE, GLUCOCEREBROSIDASE, ASPARAGINASE AND ADENOSINE DEAMINASE; TRANSCRIPTION FACTORS AND TRANSCRIPTIONAL MODULATORS; CARBOHYDRATES, GLYCOSOAMINOGLYCANS, GLYCOPROTEINS AND POLYSACCHARIDES; LIPIDS, NAMELY, PHOSPHATIDYL-ETHANOLAMINE, PHOSPHATIDYLSERINE AND DERIVATIVES THEREOF; SPHINGOSINE; STEROIDS, NAMELY, CHOLESTEROL AND DERIVATIVES THEREOF; NUCLEOTIDES, NUCLEOSIDES, HETEROCYCLIC BASES, DNA, RNA, SYNTHETIC AND NON-SYNTHETIC OLIGONUCLEOTIDES INCLUDING THOSE WITH NUCLEASE RESISTANT BACKBONES; VITAMINS; ANTIBIOTICS; BACTERISTATIC AND BACTERICIDAL AGENTS; ANTIFUNGAL, ANTHELMINTHIC AND OTHER AGENTS EFFECTIVE AGAINST INFECTIVE AGENTS INCLUDING UNICELLULAR PATHOGENS; SMALL EFFECTOR MOLECULES, NAMELY, NORADRENALIN, ALPHA ADRENERGIC RECEPTOR LIGANDS, DOPAMINE RECEPTOR LIGANDS, HISTAMINE RECEPTOR LIGANDS, GABAIBENZODIAZEPINE RECEPTOR LIGANDS, SEROTONIC RECEPTOR LIGANDS, LEUKOTRIENES AND TRIIODOTHYRONINE; CYTOTOXIC AGENTS SUCH AS DOXORUBICIN, METHOTREXATE AND DERIVATIVES THEREOF; VACCINES, NAMELY, HEPATITIS-B VACCINE, MALARIA VACCINE, MELANOMA VACCINE AND HIV-1 VACCINEACTIVE—
010CATHETERS; STENTS AND PARTS AND FITTINGS FOR THESE GOODSACTIVE—
042RESEARCH AND CONSULTANCY SERVICES RELATING TO PHARMACEUTICALS, VETERINARY PRODUCTS, SANITARY PRODUCTS, GENE THERAPY, CANCER TREATMENT AND POLYMERTECHNOLOGY IN MEDICINE; LICENSING OF INTELLECTUAL PROPERTY, NAMELY, TECHNOLOGY LICENSING SERVICES RELATING TO PHARMACEUTICALS, VETERINARY PRODUCTS, SANITARY PRODUCTS, GENE THERAPY, CANCER TREATMENT AND POLYMER TECHNOLOGYACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

Latest event (ABN2): The trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time.

DateCodeEventWhat it means
Mar 9, 2003ABN2ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSEThe trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time.
Jul 16, 2002CNSIINQUIRY AS TO SUSPENSION MAILED—
May 18, 2001CNSLLETTER OF SUSPENSION MAILED—
Jan 17, 2001CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Jul 17, 2000CNRTNON-FINAL ACTION MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Jul 3, 2000DOCKASSIGNED TO EXAMINER—
Jun 28, 2000DOCKASSIGNED TO EXAMINER—

Frequently asked questions

Related guidance